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TNF-related apoptosis-inducing ligand (TRAIL APO-2L) is a member of the TNF family and induces apoptosis in cancer cells without
affecting most non-neoplastic cells. The present investigation is focused on apoptosis induction by combined exposure to TRAIL and
ionising radiation (IR) in human renal cell carcinoma (RCC) cell lines. Here, we demonstrate that all RCC cell lines coexpress TRAIL
and the death-inducing receptors, TRAIL-R1 and TRAIL-R2. Exposure to TRAIL alone induced marked apoptosis in three out of eight
RCC cell lines. Combined exposure to TRAIL and IR resulted in a sensitisation to TRAIL-induced apoptosis in one RCC cell line only.
Enhanced apoptosis induction by TRAIL in combination with IR was paralleled by an increase in PARP cleavage and activation of
executioner caspase-3, whereas caspases-6 and -7 were not involved. Moreover, exposure to TRAIL and/or IR resulted in a marked
activation of initiator caspase-8, possibly augmented by the observed reduction of inhibitory c-FLIP expression. In contrast to other
tumour types, activation of initiator caspase-9 was not detectable in our RCC model system after exposure to TRAIL and/or IR. This
lack of caspase-9 activation might be related to an impaired ‘crosstalk’ with the caspase-8 pathway as suggested by the missing Bid
cleavage and to the appearance of an XIAP cleavage product known to inhibit caspase-9 activation. Deficient activation of caspase-9,
therefore, might contribute to the clinically known resistance of human RCC against IR and also argues against an effective
combination therapy with TRAIL and IR in this tumour type.
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Resistance of malignant tumours including human renal cell
carcinoma (RCC) to chemotherapy and ionising radiation (IR)
remains a major problem in oncology and is, at least in part,
explained by defects in apoptotic pathways (Lowe et al, 1993;
Mulders et al, 1997; Mu ¨ller et al, 1998; Zhivotovsky et al, 1999;
Verheij and Bartelink, 2000; Igney and Krammer, 2002). Especially
the pathways of IR-induced apoptosis are not well understood so
far. It is thought, however, that IR-induced apoptosis is primarily
executed via release of cytochrome c from mitochondria and
subsequent activation of the caspase-9 pathway (Zhivotovsky et al,
1999; Belka et al, 2000, 2001; Newton and Strasser, 2000; Joseph
et al, 2001; Rudner et al, 2001). In addition, activation of caspase-8
has been observed during IR-induced apoptosis, which could be
related to the activation of TRAIL-R2 death receptors (Belka et al,
2000). The corresponding TRAIL ligand (APO-2L) is a type II
transmembrane protein, which induces apoptosis through the
specific interaction with the two death receptors TRAIL-R1 (DR4)
and -R2 (DR5), both exhibiting a death domain in their
cytoplasmatic regions (for a review, see Walczak and Krammer,
2000). In addition, TRAIL also binds to the decoy receptors
TRAIL-R3 (DcR1) and -R4 (DcR2), which lack a functional
cytoplasmatic death domain and therefore cannot induce apopto-
sis. TRAIL-induced apoptosis was reported to be primarily
mediated via activation of caspase-8 (Gong and Almasan, 2000;
Yamanaka et al, 2000; Belka et al, 2001; Nimmanapalli et al, 2001;
Suliman et al, 2001; Sun et al, 2001) but might also result from the
proteolytic activation of Bid, which mediates the release of
cytochrome c from mitochondria, thereby additionally activating
caspase-9 (Belka et al, 2001; Eggert et al, 2001; Nimmanapalli et al,
2001; Seol et al, 2001; Suliman et al, 2001; Sun et al, 2001). The
simultaneous activation of both pathways, that is, the activation of
caspase-8 and caspase-9, is thought to result in an further
amplification of the original apoptosis signal. Both pathways
subsequently converge in the activation of executioner caspase-3,
which in turn cleaves a set of cellular substrates resulting in
apoptosis (Belka et al, 2000, 2001; Walczak and Krammer, 2000;
Joseph et al, 2002).
TRAIL was shown to exhibit potent antitumour activity upon
systemic administration in vivo without the deleterious side effects
on normal tissues known from CD95-ligand (Ashkenazi et al, 1999;
Walczak et al, 1999; Nagata, 2000). Our group (Dejosez et al, 2000)
and others (Ashkenazi et al, 1999; Pawlowski et al, 2000; Oya et al,
2001) also observed responsiveness to TRAIL-mediated apoptosis
in some RCC cell lines, raising the possibility that TRAIL, either
alone or in combination with other therapeutic strategies, might
become a cancer therapeutic for otherwise unresponsive RCCs.
Thus, a synergistic enhancement of TRAIL-mediated apoptosis by
different anticancer drugs could be demonstrated in RCC cell lines
suggesting that TRAIL might overcome resistance of RCC cells
against anticancer drug-induced apoptosis (Dejosez et al, 2000;
Mizutani et al, 2002).
The combination of TRAIL with IR might become another
therapeutic option in order to overcome apoptosis resistance of
tumour cells and several reports could actually demonstrate
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san additive or synergistic effect in different tumour models
(Chinnaiyan et al, 2000; Gong and Almasan, 2000; Belka et al, 2001;
Di Pietro et al, 2001; Kim et al, 2001a; Ravi et al, 2001). As
corresponding investigations are missing for RCCs so far, we
analysed the effects of combined treatment with TRAIL and IR
in well-characterised human RCC cell lines of the clear cell type
(Gerharz et al, 1993, 1994).
MATERIALS AND METHODS
Cells and culture
All eight cell lines used in this study were derived from typical
representatives of the clear cell (clearCa-2, -4, -6, -7, -14, -20, -22
and -23) type of RCC (Gerharz et al, 1993, 1994). The cell lines
were maintained with Dulbeccos’s modified Eagle’s medium
(DMEM, Gibco, Karlsruhe, FRG), supplemented with 10% foetal
calf serum (FCS), penicillin and streptomycin (¼standard growth
medium) and cultivated at 371C in an atmosphere with 5% CO2.
DNA extraction, polymerase chain reaction (PCR)
amplification and analysis of p53 mutations
Extraction of genomic DNA was performed using the QIAmp
Tissue Kit (Qiagen, Hildeu, FRG) according to the manufacturer’s
protocol. For amplification of p53 exons 5–9, the following
oligonucleotide primers were used:
exons 5 and 6: forward: 50-TTC CTC TTC CTG CAG TAC TC-30
reverse: 50-ATG TGC AAA CCA GAC CTC AG -30
exons 7 and 8: forward: 50-GTG TTG TCT CCT AGG TTG GC-30
reverse: 50-AAG TGA ATC TGA GGC ATA AC-30
exon 9: forward: 50-GTT ATG CCT CAG ATT CAC TT-30
reverse: 50-TTG AGT GTT AGA CTG GAA AC 30
Each amplification reaction was carried out in a total volume of
50ml containing 200ng of genomic DNA, 100pmol of each primer,
10nM of each dNTP, 2U Taq polymerase and 1 PCR reaction
buffer (Sigma, Seelze, FRG). After an initial denaturation step at
941C for 2min, 35 cycles of denaturation at 941C for 30s, annealing
at 501C for 40s, and extension at 721C for 1min as well as a last
delay at 721C for 10min were performed on a PTC-100-
thermocycler (MJ-Research, USA). After amplification, 5mlo f
each PCR reaction was analysed by electrophoresis on a 1.5%
agarose gel and visualised by ethidium-bromide staining.
The PCR products were purified from surplus oligonucleotides
using Microspin S-300 columns (Pharmacia, Erlangen, FRG). The
purified PCR products were prepared for automatic sequencing
using the ABI-Prism BigDye Terminator Cycle Sequencing Kit
(Perkin–Elmer, Rodgau, FRG) according to the manufacturer’s
protocol. Sequence analysis was carried out with the sense (50) and
the antisense (30) primers using an ABI-Prism 310 sequencer
(Perkin–Elmer, Rodgau, FRG). p53 mutations were verified by an
independent PCR amplification of genomic DNA followed by a
repeated DNA sequencing.
RNA extraction and reverse transcription (RT)–PCR
analysis of TRAIL and its receptors
Total cellular RNA was isolated from RCC cell lines using the
RNeasy kit (Qiagen, Hildeu, FRG). RNA concentration was
measured by photometry at 260nm. The quality of total cellular
RNA was verified by the integrity of 18S/28S ribosomal RNA in
ethidium bromide-stained agarose gels.
For monitoring expression of TRAIL and its R1-, R2-, R3- and
R4-receptors, RT was performed using an RT-kit (Stratagene,
La Jolla, USA), 5mg of total cellular RNA, 10pmol of gene-specific
antisense primer (TRAIL-R3) or 100pmol random primer (TRAIL,
R1, R2, R4 and GAPDH) and 5U AMV reverse transcriptase
(Promega, Madison, USA) with the corresponding RT buffer in a
final volume of 30ml. The reactions were incubated at 551C for 1h.
T h eP C Rm i x t u r ew a sc o m p o s e da sf o l l o w s :1 . 5 mlo ft h ec D N A
solution as a template, 25pmol of each gene-specific primers,
12.5nmol of dNTPs (Stratagene, La Jolla, USA) and 2.5U Taq
polymerase (Sigma, Seelze, FRG) with the corresponding buffer in a
f i n a lv o l u m eo f5 0ml.
The following primer sequences were used:
TRAIL: forward: 50-ACA GCA GTC AGA CTC TGA CAG GAT C-30
reverse: 50-ACG GAG TTG CCA CTT GAC TTG CCA G-30
TRAIL-R1: forward: 50-CAG AAC GTC CTG GAG CCT GTA AC-30
reverse: 50-ATG TCC ATT GCC TGA TTC TTT GTG-30
TRAIL-R2: forward: 50-GAT TGT ACA CCC TGG AGT GAC ATC G-30
reverse: 50-CCA CAG TAA AGA CTT GCA AAC AAA CAC-30
TRAIL-R3: forward: 50-CTG CCA GTC CTA GCT TAC TCT G-30
reverse: 50-CTG CTA CAC TTC CGG CAC ATC T-30
TRAIL-R4: forward: 50-GAC CCC AAG ATC CTT AAG TTC G-30
reverse: 50-TGT TCT ACA CGT CCG GCA CAT C-30
GAPDH: forward: 50-ACG GAT TTG GTC GTA TTG GGC G-30
reverse: 50-CTC CTG GAA GAT GGT GAT GG-30
The initial denaturation step at 941C for 4min was followed by
35 cycles (or 27 cycles for GAPDH) of denaturation for 1min
(TRAIL and TRAIL-R1, -R2, -R3, -R4) or 30s (GAPDH), annealing
for 1min at 551C (TRAIL and TRAIL-R1, -R2, -R3, -R4) or 641C
(GAPDH), extension at 721C for 1min, and a final extension step at
721C for 10min. The PCR products were separated on 3% agarose
gels and the identity of the amplification products was confirmed
by DNA sequencing (data not shown).
Assessment of cell number after exposure to rhs TRAIL
and/or IR
Recombinant human soluble (rhs) TRAIL (Pepro Tech, Rocky Hill
USA) was added to the cultures to yield a final concentration of 10
and 100ngml
 1, respectively. In an other set of experiments,
cultures were exposed to IR with doses of 1 or 5Gy. Four replicate
24-well plates were exposed to standard growth medium supple-
mented with 10 or 100ngml
 1 rhs TRAIL or exposed to IR with 1
or 5Gy, respectively. Moreover, two replicate 24-well plates with
standard growth medium were first exposed to IR (1 or 5Gy) and
afterwards exposed to standard growth medium supplemented
with 10ngml
 1 rhs TRAIL. 5 10
4 cells were seeded in each
culture plate. As controls, two replicate 24-well plates received
inocula of 5 10
4 cells in standard growth medium. In each
experiment, cells were harvested separately after 72h. Cells were not
refed during this period. The assessment of cell number was
performed in three independent experiments (n¼3). The number of
cells harvested was counted by the trypan-blue exclusion method.
Statistical analysis
Interactions between rhs TRAIL and IR were analysed by the
fractional inhibition method as follows: when expressed as the
fractional inhibition cell viability, additive inhibition produced by
both inhibitors (i) occurs when i1,2¼i1þi2; synergism when
i1,24i1þi2; and antagonism when i1,2oi1þi2.
Morphological assessment of TRAIL-induced apoptosis
1 10
4 cells were seeded in each chamber of eight-chamber slides
(Nunc, Wiesbaden, FRG). After 24h, the cells were treated with 10
or 100ngml
 1 rhs TRAIL and cultured for another 72h. As a
control, tumour cells were exposed to standard growth medium.
Apoptosis was determined by light microscopy of haematoxylin–
eosin (HE)-stained cells showing the typical morphological signs
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sof apoptosis, that is, chromatin condensation and/or fragmenta-
tion into apoptotic bodies (Gerharz et al, 1999; Ramp et al, 2000,
2001).
Western blot analysis
Ten replicate 25cm
2 culture flasks, each containing inocula of
1 10
6 cells, were exposed to standard growth medium supple-
mented with rhs TRAIL (10ngml
 1) or exposed to IR (1Gy),
respectively. Moreover, five replicate 25cm
2 culture flasks with
standard growth medium were first exposed to IR (1Gy) and
afterwards exposed to standard growth medium supplemented
with rhs TRAIL (10ngml
 1). As controls, six replicate 25cm
2
culture flasks received inocula of 1 10
6 cells in standard growth
medium. In each experiment, cells were harvested separately after
0.5, 3, 6, 12 and 24h or after 12h (for analysis of c-FLIP, FADD,
Bid, phosphorylated Akt, XIAP and survivin). Cells were not refed
during this period.
For Western blot analysis, tumour cells were lysed in a buffer
containing 100mM NaCl, 10mM Tris-HCl (pH 7.6), 1mM EDTA
(pH 8.0), 1mgml
 1 aprotinin, 100mgml
 1 phenylmethylsulphonyl
fluoride and 1% NP40. Protein (50mg) was analysed by SDS–PAGE
and protein expression levels were determined by immunoblotting
with the following monoclonal or polyclonal antibodies: caspase-3
(1:150, Cell Signaling Technology, Beverly, USA), caspase-6
(1:1000, Cell Signaling Technology, Beverly, USA) caspase-7
(clone B94-1; 1:1000, Pharmingen, San Diego, USA), caspase-8
(clone 1C12; 1:1000, Cell Signaling Technology, USA), caspase-9
(clone 1–2; 1:500, Oncogene, La Jolla, USA), Bid (1:500,
Biosource, Camarillo, FRG), phosphorylated Akt (clone 4E2;
1:1000, Cell Signaling Technology, Beverly, USA), Fas-associated
death domain-containing protein (FADD) (clone A66-2; 1:1000,
Pharmingen, San Diego, USA), PARP (clone 4C10-5; 1:1000,
Pharmingen, San Diego, USA), X-linked inhibitor of apoptosis
proteins (XIAP) (clone 48; 1:250, Transduction Laboratories,
Lexington, USA), Survivin (1:1000, Novus Biologicals, Littleton,
USA) and c-FLICE-inhibitory protein (FLIP) (clone NF6, 1:10, gift
from Professor Dr P Krammer, DKFZ, Heidelberg).
For detection, the ECL detection system (Fa. Amersham,
Freiburg, FRG) was used according to the manufacturer’s
instructions. Equal loading of the gels was confirmed both by
Commassie-blue staining of control gels and by reincubation of the
filters with a monoclonal antibody for a-tubulin (clone B-5-1-2;
1:5000, Sigma-Aldrich, Seelze, FRG).
RESULTS
TRAIL-mediated apoptosis in human RCCs
Reverse transcription–polymerase chain reaction RT–PCR analy-
sis revealed coexpression of TRAIL ligand as well as apoptosis-
inducing TRAIL-R1 and -R2 in all RCC cell lines (Figure 1).
Moreover, two different specific amplification products (120 and
217bp) of TRAIL-R2 were detectable in all cell lines and verified as
TRICK-2A and TRICK-2B by sequence analysis (data not shown).
All RCCs expressed antagonistic TRAIL-R3 and -R4 with weak
signals for TRAIL-R3 in the majority of cell lines (Figure 1).
To evaluate the extent of TRAIL-mediated apoptosis and the
functionality of the TRAIL-signalling pathway, we used rhs TRAIL,
thereby confronting our RCC cell lines with an uniform apoptotic
signal. After exposure to rhs TRAIL (10 or 100ngml
 1) for 72h, a
heterogeneous response was observed with a marked decrease of
cell viability in only three out of eight RCC cell lines (clearCa-6, -14
and –23) (Figure 2). The decrease of cell viability after exposure to
TRAIL was paralleled by a marked induction of apoptosis
(Figure 3), as became evident from light microscopical evaluation
of HE-stained cells, which had been shown to be a highly sensitive
and specific method for the assessment of apoptosis (Gerharz et al,
1999; Ramp et al, 2000, 2001).
p53 status
As wild-type p53 has been reported to be involved in apoptosis
induction after exposure to TRAIL and/or IR (Lowe et al, 1993;
Chinnaiyan et al, 2000), we additionally defined the mutational
status of p53 in our RCC cell lines. Sequencing of p53 exons 5–9,
which are the most commonly affected hot spot regions for p53
mutations in human RCC (Reiter et al, 1993), revealed p53 exon
mutations in two of eight RCC cell lines only (Table 1). The p53
status, however, could not be correlated with the sensitivity to
TRAIL-induced apoptosis. Thus, mutant p53 was observed in
clearCa-6, which is highly TRAIL-sensitive, but also in clearCa-4,
which is TRAIL-resistant.
Ionising radiation sensitises to TRAIL-induced apoptosis
in a minority of RCCs
To evaluate a possible increase in sensitivity against TRAIL-
induced apoptosis by IR, we selected TRAIL-resistant RCC cell
lines (clearCa-2, -4, -7, -20 and -22) and the most TRAIL-sensitive
cell line (clearCa-6) for the combined exposure to TRAIL
(10ngml
 1) and clinically relevant IR doses (1 or 5Gy). In these
experiments, combined exposure to TRAIL and IR resulted in a
sensitisation effect with marked enhancement of apoptosis in one
RCC cell line only (clearCa-22) (Figure 4). Interestingly, this cell
line did not harbour a mutation in the p53 ‘hot spot’ exons and
had shown increased expression of TRAIL-R2 protein after IR by
Western blot analysis (data not shown). In accordance, a strong
enhancement of apoptosis induction also became evident from a
marked increase in PARP cleavage after combined exposure of
clearCa-22 to TRAIL and IR, whereas exposure to either TRAIL or
IR alone did not result in increased levels of PARP cleavage
(Figure 5A). Combined exposure of clearCa-22 to TRAIL and IR
also resulted in a marked caspase-3 activation, whereas exposure
to either TRAIL or IR alone induced no (TRAIL) or a weak (IR)
caspase-3 cleavage only (Figure 5B). In contrast, activation of
executioner caspase-6 and -7 was not detectable (Figure 5C, D).
Figure 1 Expression of TRAIL and its receptors in eight human RCC cell
lines by RT–PCR. TRICK-2A and TRICK-2B are alternative splicing variants
of TRAIL-R2. GAPDH detection was used as control for integrity of RNA
and RT–PCR reactions.
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sCleavage of caspase-8, but not of caspase-9 triggers TRAIL-
and/or IR-mediated apoptosis in RCC
Since the sensitisation to apoptosis induction after combined
exposure to TRAIL and IR may be due to the simultaneous
activation of the caspase-8 and -9 pathways, we next analysed the
activation of these distinct apoptosis pathways in clearCa-22.
As shown in Figure 6A, cleavage of initiatior caspase-8 into its
fragments (p43 and p41) became evident in clearCa-22 after
exposure to TRAIL and/or IR. Of note, caspase-8 activation after
combined exposure to TRAIL and IR did not exceed the effects of
each treatment alone, although only combined exposure had
resulted in an increased cleavage of caspase-3. Interestingly in this
context, expression of caspase-8-inhibitory c-FLIP (Irmler et al,
1997; Wang et al, 2000) was markedly reduced after exposure to
TRAIL or IR alone and in combination, thereby probably
contributing to the activation of caspase-8 (Figure 7). In contrast,
no unequivocal differences in the expression of FADD became
evident after exposure to TRAIL and/or IR (Figure 7).
Figure 2 Response of human RCC cell lines to TRAIL-induced cell death.
Cells were cultured for 72h in the presence of TRAIL (grey bars:10ngml
 1
TRAIL; black bars: 100ngml
 1 TRAIL) and the number of surviving,
nonapoptotic cells is demonstrated in percentage of viable cells in the
control (bars represent the s.d).
Figure 3 Marked induction of apoptosis (arrows) and marked reduction
of cell density in clearCa-6 cells after exposure to TRAIL (100ngml
 1)( B)
when compared to the control (A). (Before TRAIL treatment, about 2% of
the cells exhibited morphological features of apoptosis. The proportion of
apoptotic cells after TRAIL treatment, however, cannot exactly be
determined, because most apoptotic cells detached from the bottom of
the culture flask and formed a not exactly quantifiable mass of cell detritus
in the supernatant).
Figure 4 Sensitisation to TRAIL-induced apoptosis by IR in one
(clearCa-22) out of six human RCC cell lines. RCC cell lines were cultured
for 72h in the presence of TRAIL (10ngml
 1) or IR (1 or 5Gy) alone or in
combination and the number of surviving, nonapoptotic cells is demon-
strated in percentage of viable cells in the control (bars represent the s.d).
Table 1 p53 mutation status
Cell line p53 (wild-type (wt) or mutation (mt))
2 mt in noncoding region: codon 306: CGA-CAA
4 mt: exon 8, codon 273: CGA-CAT
6 mt: exon 8, codon 290: CGC-CAC
7w t
14 wt
20 wt
22 mt in noncoding region: codon 331: CTT-CTC
23 wt
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sIn contrast to activation of the caspase-8 pathway, activation of
the caspase-9 pathway was not detectable in clearCa-22 at all
(Figure 6B). Since the caspase-9 pathway was shown to be
functionally involved in IR-induced apoptosis in other tumour
models (Newton and Strasser, 2000; Joseph et al, 2001; Rudner et al,
2001), the impaired activation of caspase-9 might contribute to the
well-known resistance of RCC to IR-induced apoptosis.
Moreover, our investigations provided first clues to the
mechanisms of deficient caspase-9 activation in RCC. Thus,
cleavage of Bid into tBid, which is the connecting link between
the caspase-8 and caspase-9 pathways of apoptosis induction (Li
et al, 1998), could not be observed after exposure to TRAIL and/or
IR (Figure 7). Failure of Bid cleavage could not be attributed to the
presence of active phosphorylated Akt protein, which was not
detectable at all (Figure 7). Moreover, high levels of XIAP
expression were observed before and after exposure to TRAIL
and/or IR (Figure 7) and, more importantly, a cleavage product of
XIAP, which is known to inhibit caspase-9 activation (Deveraux
et al, 1999), appeared after exposure to TRAIL and/or IR (Figure 7).
In contrast, only low expression levels of antiapoptotic survivin,
known to inhibit activation of caspase-3, -7 and -9, were found
before and after exposure to TRAIL and/or IR (Figure 7).
DISCUSSION
Ionising radiation is thought to exert its therapeutic effects, at least
in part, by induction of apoptosis in tumour cells (Brown and
Wouters, 1999; Zhivotovsky et al, 1999; Newton and Strasser, 2000;
Verheij and Bartelink, 2000). As TRAIL has recently been shown to
induce apoptosis effectively in tumour cells (Ashkenazi et al, 1999;
Walczak et al, 1999; Dejosez et al, 2000; Nagane et al, 2000;
Walczak and Krammer, 2000) but not in normal cells (Walczak
et al, 1999; Kim et al, 2001b), this death ligand could be used in
combination with IR in anticancer treatment. Therefore, we
analysed whether the combined actions of TRAIL and IR
effectively overcome the clinically known resistance of human
RCCs against induction of apoptosis.
Figure 5 Western blot analysis demonstrating marked cleavage of PARP (p85; A) and procaspase-3 (p17/p12; B) into its active fragments after combined
exposure of clearCa-22 cells to TRAIL (10ngml
 1) and IR (1Gy). Exposure to TRAIL or IR alone did not result in increased cleavage. No cleavage products
of procaspases-6 (p15; C) and -7 (p17; D) in clearCa-22 cells after exposure to TRAIL or IR alone and in combination. (cleavage of PARP as well as the
procaspase-3, -6, and -7 in J16 cells after exposure to CH11 (500ngml
 1) was used as a positive control). Expression of a-tubulin (E) shows equal amounts
of protein loaded in each lane.
Figure 6 Western blot analysis demonstrating marked cleavage of procaspase-8 (A) into its active p43- and p41-fragments after exposure of clearCa-22
cells to TRAIL (10ngml
 1) or IR (1Gy) alone and in combination. No cleavage of procaspase-9 (B) in clearCa-22 cells after exposure to TRAIL or IR alone
and in combination. (cleavage of procaspase-8 and -9 in J16 cells after exposure to CH11 (500ngml
 1) was used as a positive control). Expression of a-
tubulin (C) shows equal amounts of protein loaded in each lane.
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sThe data presented here demonstrate expression of apoptosis-
inducing TRAIL-R1- and -R2-receptors in all RCC cell lines.
Moreover, recombinant TRAIL was capable of inducing marked
apoptosis in three out of eight cell lines. This observation was
important in that it proved the existence of a functionally active
mechanism of self-destruction in a significant proportion of RCCs,
provided that appropriate stimuli can be applied or sensitivity to
weak stimuli can be raised. Despite the presence of proapoptotic
TRAIL-R1 and -R2 receptors in all cell lines, however, therapeu-
tically relevant doses of IR combined with TRAIL treatment largely
failed to increase the apoptotic response in most of our RCC cell
lines. Thus, a sensitisation effect with marked enhancement of
apoptosis after combined TRAIL and IR treatment was observed in
one out of six RCC cell lines only. These observations were at
variance with much more favourable recent reports on synergistic
effects of TRAIL and IR in breast and colon carcinoma cell lines
(Chinnaiyan et al, 2000; Ravi et al, 2001) as well as Jurkat cells
(Gong and Almasan, 2000; Kim et al, 2001a). It has to be
considered, however, that only short-term effects of TRAIL and IR
becoming evident within 72h could be assessed under the
conditions of our experiments, whereas potential long-term effects
of IR were not within the scope of our investigation.
Little is known concerning the mechanisms underlying the
resistance to TRAIL and/or IR. However, it is thought that
apoptosis induction in response to IR requires an intact p53
system (Lowe et al, 1993), and, accordingly the synergistic effect of
TRAIL and IR in breast carcinomas was reported to depend on a
p53 wild-type status (Chinnaiyan et al, 2000). One possible
mechanism promoting the synergistic effect of TRAIL and IR
might involve the upregulation of TRAIL-R2, known to be a
downstream effector gene of p53 (Yu et al, 1999). Actually,
irradation resulted in an increase of TRAIL-R2 expression in
clearCa-22 (which does not harbour mutations in p53-coding
regions), thereby possibly rendering this cell line more sensitive to
TRAIL-induced apoptosis. Nevertheless, the overall level of
apoptosis induction in clearCa-22 after combined exposure to
TRAIL and IR was rather low (maximal decrease of cell number:
46.871.5% of the control) when compared with the effects
observed in a colon carcinoma cell line (Ravi et al, 2001) and in
different clones of Jurkat cells (Belka et al, 2001; Kim et al, 2001a).
According to current concepts, apoptosis can be induced via at
least two distinct, but interconnected pathways that activate
different initiator caspases, that is, caspase-8 and -9, which
converge at the level of executioner caspase-3, -6, and -7. The
simultaneous activation of both pathways is thought to result in a
strong amplification of the original apoptosis signal (Li et al, 1998;
Belka et al, 2000, 2001; Suliman et al, 2001; Joseph et al, 2002). We,
therefore, analysed the activation status of these two principal
pathways in clearCa-22 after exposure to TRAIL or IR alone and in
combination. In these investigations, we could demonstrate
cleavage of the executioner caspase-3 in clearCa-22 only after
combined exposure to TRAIL and IR, whereas exposure to TRAIL
or IR alone resulted in no or barely detectable caspase-3 cleavage
only. In accordance, cleavage of PARP, known to be a substrate of
active caspase-3 (Yang et al, 2001), became evident in clearCa-22
only after combined exposure to TRAIL and IR. Therefore,
activation of caspase-3, which was previously shown to be involved
in TRAIL- and IR-induced apoptosis in other tumour types
(Griffith et al, 1998; Gong and Almasan, 2000; Yamanaka et al,
2000; Belka et al, 2001; Joseph et al, 2001, 2002; Kim et al, 2001a;
Nimmanapalli et al, 2001; Rudner et al, 2001; Suliman et al, 2001;
Sun et al, 2001; Joseph et al, 2002), is also found in RCCs. At
variance with other tumour types (Coelho et al, 2000; Sun et al,
2001; Yang et al, 2001), however, no cleavage of executioner
caspase-6 or -7 became evident in our RCC model system.
Since caspase-3 can be activated by both principal apoptosis
signalling pathways involving the initiator caspase-8 or -9,
respectively, we next analysed the functional contribution of these
distinct apoptosis pathways. Thus, we could demonstrate a strong
cleavage of the initiator caspase-8 in clearCa-22 after exposure to
TRAIL or IR alone and in combination. These findings are in line
with reports demonstrating caspase-8 cleavage after exposure to
TRAIL or IR in RCCs (Pawlowski et al, 2000) and many other
tumour types, including carcinomas of the liver, prostate and lungs
(Yamanaka et al, 2000; Nimmanapalli et al, 2001; Sun et al, 2001),
melanoma (Griffith et al, 1998) and Jurkat cells (Gong and
Almasan, 2000; Belka et al, 2001; Kim et al, 2001a; Rudner et al,
2001; Suliman et al, 2001). Activation of caspase-8 by TRAIL or IR,
therefore, seems to be a common reaction pattern in a variety of
different tumour types, including RCCs. Of note, a marked
downregulation of c-FLIP protein, which is able to inhibit
caspase-8 activation (Irmler et al, 1997), became evident in
clearCa-22 after exposure to TRAIL and/or IR. Although the role of
c-FLIP in inhibiting TRAIL-induced apoptosis is controversial
(Griffith et al, 1998; Pawlowski et al, 2000; Wang et al, 2000;
Mitsiades et al, 2001), these results suggest that reduced c-FLIP
might be involved in the activation of caspase-8 in RCCs.
Activation of initiator caspase-9 after exposure to TRAIL or IR
was reported in carcinomas of the prostate and lung (Nimmana-
palli et al, 2001; Joseph et al, 2001; Sun et al, 2001), Ewing’s
sarcoma (Mitsiades et al, 2001) and Jurkat lymphoma cells (Kim
et al, 2001a; Rudner et al, 2001). In contrast, we could not detect
any cleavage of inactive procaspase-9 into active caspase-9 in
clearCa-22 after exposure to TRAIL and/or IR. Therefore,
Figure 7 Western blot analysis of apoptosis-regulating proteins in
clearCa-22 after exposure to TRAIL (10ngml
 1) or IR (1Gy) alone and in
combination for 12h. Reduced expression of c-FLIP after exposure to
TRAIL and/or IR, whereas expression of FADD and survivin remained
unchanged when compared with the control (0). No cleavage of Bid into
tBid and absence of active phosphorylated Akt protein after exposure to
TRAIL and/or IR. High levels of XIAP protein (53kDa) before and after
exposure to TRAIL and/or IR and appearance of an XIAP cleavage product
after exposure to TRAIL and/or IR. (Cleavage of Bid into tBid in J16 cells
after exposure to CH11 was used as a positive control; expression of
phosphorylated Akt in PDGF-induced NIH-3T3 cells was used as a positive
control, as recommended by the manufacturer).
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caspase-9 pathway seems to be blocked in our RCC model system.
Our investigation suggests that lack of Bid cleavage might
contribute to the failure of caspase-9 activation. Thus, it is known
that active caspase-8 is able to cleave Bid into tBid, which
translocates to mitochondria, causing cytochrome c release and
activation of caspase-9 as well as caspase-3 (Li et al, 1998; Belka
et al, 2001; Kim et al, 2001a; Nimmanapalli et al, 2001; Suliman
et al, 2001). This interconnection between the caspase-8 and -9
pathway via Bid is believed to represent a strong amplification
loop of the apoptosis signal. However, no cleavage of Bid was
detectable in clearCa-22 after exposure to TRAIL and/or IR despite
cleavage of caspase-8 and -3. Another recently identified regulator
of caspase-9 and Bid is Akt, a serine/threonine protein kinase,
which is activated by phosphorylation. Interestingly, the expres-
sion of active Akt was found to correlate with TRAIL resistance in
prostate carcinomas (Thakkar et al, 2001). Akt exerts its
antiapoptotic effects through caspase-9 inactivation by phosphor-
ylation as well as direct inhibition of Bid cleavage (Thakkar et al,
2001). In clearCa-22, however, expression of active Akt was present
neither before nor after exposure to TRAIL and/or IR. In contrast
to other tumour types, therefore, Akt seems to be of minor
importance for inhibiting Bid cleavage and preventing caspase-9
activation in our RCC model system.
Moreover, a high basal expression level of the IAP family
member XIAP became evident in our RCC cell line clearCa-22.
Importantly in this context, we observed the appearance of a
cleavage product of XIAP after exposure to TRAIL and/or IR. Since
the fragment of XIAP contains the BIR3-Ring domain, which was
shown to inhibit specificially the activation of caspase-9 (Deveraux
et al, 1999), this cleavage product might also be involved in the
deficient activation of caspase-9 in our cell line. In contrast,
expression of survivin, another member of the IAP family, which
was reported to be downregulated in prostate carcinoma cells after
exposure to TRAIL (Nimmanapalli et al, 2001), was not affected in
clearCa-22 after exposure to TRAIL and/or IR.
Collectively, our results demonstrate a marked heterogeneity in
the responsiveness of human RCC cell lines to TRAIL-mediated
apoptosis. Moreover, IR resulted in a sensitisation to TRAIL-
induced apoptosis in one RCC cell line only. In addition, our
observations suggest that TRAIL- and IR-induced apoptosis in
RCC is predominantly mediated via the caspase-8 pathway,
whereas the caspase-9 pathway is not utilised. The missing
activation of the caspase-9 pathway may result from an impaired
‘cross talk’ with the caspase-8 pathway because of the lack of Bid
cleavage and from the appearance of as XIAP cleavage product
known to inhibit caspase-9 activation. Therefore, the deficient
activation of caspase-9 might contribute to the clinically known
resistance of human RCC against IR and also argues against an
effective combination therapy with TRAIL and IR in this tumour
type.
ACKNOWLEDGEMENTS
The antibody against c-FLIP was kindly provided by Professor Dr
P Krammer (DKFZ, Heidelberg, Germany). Our appreciation is
expressed to Mr Ringler for his excellent technical assistance. The
results are part of the PhD thesis of E Caliskan. The work was
supported by the ‘Deutsche Forschungsgemeinschaft’ (DFG).
REFERENCES
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie
C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D,
Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH (1999) Safety
and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest
104: 155–162
Belka C, Rudner J, Wesselborg S, Stepczynska A, Marini P, Lepple-
Wienhues A, Faltin H, Bamberg M, Budach W, Schulze-Osthoff K (2000)
Differential role of caspase-8 and BID activation during radiation- and
CD95-induced apoptosis. Oncogene 19: 1181–1190
Belka C, Schmid B, Marini P, Durand E, Rudner J, Faltin H, Bamberg M,
Schulze-Osthoff K, Budach W (2001) Sensitization of resistant lymphoma
cells to irradiation-induced apoptosis by the death ligand TRAIL.
Oncogene 20: 2190–2196
Brown JM, Wouters BG (1999) Apoptosis, p53, and tumor cell sensitivity to
anticancer agents. Cancer Res 59: 1391–1399
Chinnaiyan AM, Prasad U, Shankar S, Hamstra DA, Shanaiah M, Chenevert
TL, Ross BD, Rehemtulla A (2000) Combined effect of tumor necrosis
factor-related apoptosis-inducing ligand and ionizing radiation in breast
cancer therapy. Proc Natl Acad Sci USA 97: 1754–1759
Coelho D, Holl V, Weltin D, Lacornerie T, Magnenet P, Dufour P, Bischoff P
(2000) Caspase-3-like activity determines the type of cell death following
ionizing radiation in MOLT-4 human leukaemia cells. Br J Cancer 83:
642–649
Dejosez M, Ramp U, Mahotka C, Krieg A, Walczak H, Gabbert HE, Gerharz
CD (2000) Sensitivity to TRAIL/APO-2L-mediated apoptosis in human
renal cell carcinomas and its enhancement by topotecan. Cell Death
Differ 7: 1127–1136
Deveraux QL, Leo E, Stennicke HR, Welsh K, Salvesen GS, Reed JC (1999)
Cleavage of human inhibitor of apoptosis protein XIAP results in
fragments with distinct specificities for caspases. EMBO J 18:
5242–5251
Di Pietro R, Secchiero P, Rana R, Gibellini D, Visani G, Bemis K, Zamai L,
Miscia S, Zauli G (2001) Ionizing radiation sensitizes erythroleukemic
cells but not normal erythroblasts to tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective
upregulation of TRAIL-R1. Blood 97: 2596–2603
Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, Brodeur
GM (2001) Resistance to tumor necrosis factor-related apoptosis-
inducing ligand-induced apoptosis in neuroblastoma cells correlates
with a loss of caspase-8 expression. Cancer Res 61: 1314–1319
Gerharz CD, Moll R, Sto ¨rkel S, Ramp U, Thoenes W, Gabbert HE (1993)
Ultrastructural appearence and cytoskeletal architecture of the clear,
chromophilic, and chromophobe types of human renal cell carcinoma in
vitro. Am J Pathol 142: 851–859
Gerharz CD, Ramp U, Dejosez M, Mahotka C, Czarnotta B, Bretschneider
U, Lorenz I, Mu ¨ller M, Krammer PH, Gabbert HE (1999) Resistance to
CD95 (APO-1/Fas)-mediated apoptosis in human renal cell carcinomas:
an important factor for evasion from negative growth control. Lab Invest
79: 1521–1534
Gerharz CD, Ramp U, Olert J, Moll R, Sto ¨rkel S, Marx N, Gabbert HE (1994)
Cytomorphological, cytogenetic, and molecular biological characteriza-
tion of four new human renal carcinoma cell lines of the clear cell type.
Virchows Arch 424: 403–409
Gong B, Almasan A (2000) Apo2 ligand/TNF-related apoptosis inducing
ligand and death receptor 5 mediate the apoptotic signaling induced by
ionizing radiation in leukemic cells. Cancer Res 60: 5754–5760
Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ (1998)
Intracellular regulation of TRAIL-induced apoptosis in human melano-
ma cells. J Immunol 161: 2833–2840
Igney FH, Krammer PH (2002) Death and anti-death: tumour resistance to
apoptosis. Nat Rev Cancer 4: 277–288
Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V,
Bodmer JL, Schro ¨ter M, Burns K, Mattmann C, Rimoldi D, French LE,
Tschopp J (1997) Inhibition of death receptor signals by cellular FLIP.
Nature 388: 190–195
Joseph B, Ekedahl J, Lewensohn R, Marchetti P, Formstecher P,
Zhivotovsky B (2001) Defective caspase-3 relocalization in non-small
cell lung carcinoma. Oncogene 20: 2877–2888
Joseph B, Marchetti P, Formstecher P, Kroemer G, Lewensohn R,
Zhivotovsky B (2002) Mitochondrial dysfunction is an essential step
for killing of non-small cell lung carcinomas resistant to conventional
treatment. Oncogene 21: 65–77
Deficient caspase-9 cleavage in renal cell carcinoma
U Ramp et al
1806
British Journal of Cancer (2003) 88(11), 1800–1807 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
sKim MR, Lee JY, Park MT, Chun YJ, Jang YJ, Kang CM, Kim HS, Cho CK,
Lee YS, Jeong HY, Lee SJ (2001a) Ionizing radiation can overcome
resistance to TRAIL in TRAIL-resistant cancer cells. FEBS Lett 501: 179–
184
Kim K, Takimoto R, Dicker DT, Chen Y, Gazitt Y, El-Deiry WS (2001b)
Enhanced TRAIL sensitivity by p53 overexpression in human cancer but
not normal cell lines. Int J Oncol 18: 241–247
Li H, Zhu H, Xu CJ, Yuan J (1998) Cleavage of BID by caspase 8 mediates
the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491–
501
Lowe SW, Ruley HE, Jacks T, Housman DE (1993) p53-dependent apoptosis
modulates the cytotoxicity of anticancer drugs. Cell 74: 957–967
Mitsiades N, Poulaki V, Mitsiades C, Tsokos M (2001) Ewing’s sarcoma
family tumors are sensitive to tumor necrosis factor-related apoptosis-
inducing ligand and express death receptor 4 and death receptor 5.
Cancer Res 61: 2704–2712
Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T
(2002) Potentiation of the sensitivity of renal cell carcinoma cells to
TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil.
Eur J Cancer 38: 167–176
Mulders P, Figlin R, deKernion JB, Wiltrout R, Linehan M, Parkinson D,
deWolf W, Belldegrun A (1997) Renal cell carcinoma: recent progress
and future directions. Cancer Res 57: 5189–5195
Mu ¨ller M, Wilder S, Bannasch D, Israeli D, Lehlbach K, Li-Weber M,
Friedman SL, Galle PR, Stremmel W, Oren M, Krammer PH (1998) p53
activates the CD95 (APO-1/Fas) gene in response to DNA damage by
anticancer drugs. J Exp Med 188: 2033–2045
Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Su Huang HJ (2000)
Increased death receptor 5 expression by chemotherapeutic agents in
human gliomas causes synergistic cytotoxicity with tumor necrosis
factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Res
60: 847–853
Nagata S (2000) Steering anti-cancer drugs away from the TRAIL. Nat Med
6: 502–503
Newton K, Strasser A (2000) Ionizing radiation and chemotherapeutic
drugs induce apoptosis in lymphocytes in the absence of Fas or FADD/
MORT1 signaling: implications for cancer therapy. J Exp Med 191: 195–
200
Nimmanapalli R, Perkins CL, Orlando M, O’Bryan E, Nguyen D, Bhalla KN
(2001) Pretreatment with paclitaxel enhances Apo-2 ligand/tumor
necrosis factor-related apoptosis-inducing ligand-induced apoptosis of
prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Cancer Res 61: 759–763
Oya M, Ohtsubo M, Takayanagi A, Tachibana M, Shimizu N, Murai M
(2001) Constitutive activation of nuclear factor-kB prevents TRAIL-
induced apoptosis in renal cancer cells. Oncogene 20: 3888–3896
Pawlowski JE, Nesterov A, Scheinman RI, Johnson TR, Kraft AS (2000)
NF-kB does not modulate sensitivity of renal carcinoma cells to TNFa-
related apoptosis-inducing ligand (TRAIL). Anticancer Res 20:
4243–4256
Ramp U, Dejosez M, Mahotka C, Czarnotta B, Kalinski T, Wenzel M, Mu ¨ller
M, Krammer P, Gabbert HE, Gerharz CD (2000) Deficient activation of
CD95 (APO-1/Fas)-mediated apoptosis: a potential factor of multidrug
resistance in human renal cell carcinoma. Br J Cancer 82: 1851–1859
Ramp U, Mahotka C, Kalinski T, Ebel E, Gabbert HE, Gerharz CD (2001)
Topotecan (Hycamtin
s) responsiveness in human renal carcinoma cell
lines of the clear cell and papillary types. Anticancer Res 21: 3509–3518
Ravi R, Bedi GC, Engstrom LW, Zeng Q, Mookerjee B, Gelinas C, Fuchs EJ,
Bedi A (2001) Regulation of death receptor expression and TRAIL/
Apo2L-induced apoptosis by NF-kB. Nat Cell Biol 3: 409–416
Reiter RE, Anglard P, Liu S, Gnarra JR, Linehan WM (1993) Chromosome
17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 53:
3092–3097
Rudner J, Lepple-Wienhues A, Budach W, Berschauer J, Friedrich B,
Wesselborg S, Schulze-Osthoff K, Belka C (2001) Wild-type, mitochon-
drial and ER-restricted Bcl-2 inhibit DNA damage-induced apoptosis but
do not affect death receptor-induced apoptosis. J Cell Sci 114: 4161–4172
Seol DW, Li J, Seol MH, Park SY, Talanian RV, Billiar TR (2001) Signaling
events triggered by tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL): caspase-8 is required for TRAIL-induced apoptosis.
Cancer Res 61: 1138–1143
Suliman A, Lam A, Datta R, Srivastava RK (2001) Intracellular mechanism
of TRAIL: apoptosis through mitochondrial-dependent and -indepen-
dent pathways. Oncogene 20: 2122–2133
Sun SY, Yue P, Zhou JY, Wang Y, Choi Kim HR, Lotan R, Wu GS (2001)
Overexpression of Bcl2 blocks TNF-related apoptosis-inducing ligand
(TRAIL)-induced apoptosis in human lung cencer cells. Biochem Biophys
Res Commun 280: 788–797
Thakkar H, Chen X, Tyan F, Gim S, Robinson H, Lee C, Pandey SK,
Nwokorie C, Srivastava RK (2001) Pro-survival function of Akt/protein
kinase B in prostate cancer cells. J Biol Chem 276: 38361–38369
Verheij M, Bartelink H (2000) Radiation-induced apoptosis. Cell Tissue Res
301: 133–142
Walczak H, Krammer PH (2000) The CD95 (APO-1/Fas) and the TRAIL
(APO-2L) apoptosis systems. Exp Cell Res 256: 58–66
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W,
Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT,
Schuh JCL, Lynch D (1999) Tumoricidal activity of tumor necrosis
factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157–163
Wang J, Lobito AA, Shen F, Hornung F, Winoto A, Lenardo MJ (2000)
Inhibition of Fas-mediated apoptosis by the B cell antigen receptor
through c-FLIP. Eur J Immunol 30: 155–163
Yamanaka T, Shiraki K, Sugimoto K, Ito T, Fujikawa K, Ito M, Takase K,
Moriyama M, Nakano T, Suzuki A (2000) Chemotherapeutic agents
augment TRAIL-induced apoptosis in human hepatocellular carcinoma
cell lines. Hepatology 32: 482–490
Yang XH, Sladek TL, Liu X, Butler BR, Froelich CJ, Thor AD (2001)
Reconstitution of caspase-3 sensitizes MCF-7 breast cancer cells to
doxorubicin- and etoposide-induced apoptosis. Cancer Res 61: 348–354
Yu J, Zhang L, Hwang PM, Rago C, Kinzler KW, Vogelstein B (1999)
Identification and classification of p53-regulated genes. Proc Nat Acad
Sci USA 96: 14517–14522
Zhivotovsky B, Joseph B, Orrenius S (1999) Tumor radiosensitivity and
apoptosis. Exp Cell Res 248: 10–17
Deficient caspase-9 cleavage in renal cell carcinoma
U Ramp et al
1807
British Journal of Cancer (2003) 88(11), 1800–1807 & 2003 Cancer Research UK
E
x
p
e
r
i
m
e
n
t
a
l
T
h
e
r
a
p
e
u
t
i
c
s